PAX-8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX-8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX-8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX-8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX-8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.

• IHC048-PAX-8 Datasheet-RUO

• MSDS
• 2021 NordiQC Assessment Report for IHC048: Optimal
• 2022 NordiQC Assessment Report for IHC048: Optimal

CLONE:
IHC048

ISOTYPE:
IgG

HOST SPECIES:
Rabbit

CLONALITY:
Monoclonal

POSITIVE CONTROL:
Ovarian Carcinoma (Non-Mucinous Carcinoma), Thyroid Carcinoma, Renal Cell Carcinoma

DILUTION RANGE:


INTENDED USE/REG. STATUS:
RUO

ADDITIONAL INFORMATION:
NordiQC Rating: Optimal (Assessment Run 62 2021 and Run 64 2022))